May 14, 2018 / 9:13 PM / 3 months ago

BRIEF-Zymeworks And Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused On Bispecific Antibodies

May 14 (Reuters) - Daiichi Sankyo Co Ltd:

* ZYMEWORKS AND DAIICHI SANKYO EXPAND IMMUNO-ONCOLOGY COLLABORATION FOCUSED ON BISPECIFIC ANTIBODIES

* ZYMEWORKS- TO GET UPFRONT TECHNOLOGY ACCESS FEE OF $18 MILLION; MAY GET UP TO $466.7 MILLION IN POTENTIAL CLINICAL, REGULATORY, COMMERCIAL MILESTONE PAYMENTS

* ZYMEWORKS INC - ZYMEWORKS WILL RECEIVE UP TO DOUBLE-DIGIT TIERED ROYALTIES ON GLOBAL PRODUCT SALES

* ZYMEWORKS - DAIICHI SANKYO TO ACQUIRE LICENSES TO CO’S AZYMETRIC AND EFECT TECHNOLOGY PLATFORMS TO DEVELOP 2 ADDITIONAL BISPECIFIC ANTIBODY THERAPEUTICS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below